Relationship of Endometrial Cancer and Serum Soluble L1CAM Level

Kocaeli University146 enrolled

Overview

The aim of this study is to evaluate the effect of serum soluble L1CAM (sL1CAM) on the diagnosis and prognosis of endometrial cancer. This prospective randomized controlled trial will be conducted in patients who have undergone endometrial biopsy and whose pathology results are reported as benign endometrial changes, endometrial hyperplasia, or endometrial cancer. The sL1CAM level between groups will be compared. The relationship between prognostic factors and serum sL1CAM will be evaluated in patients with endometrial cancer.

Study Type

OBSERVATIONAL

Enrollment

146

Conditions

Endometrium Cancer

Interventions

serum soluble L1CAM (sL1CAM)DIAGNOSTIC_TEST

blood sample

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who underwent endometrial biopsy due to abnormal uterine bleeding and whose pathology results were reported as benign endometrial changes, endometrial hyperplasia or endometrial cancer were included in the study. All patients participating in the study signed informed consent. Exclusion Criteria: * Patients who did not have consent, received neoadjuvant therapy and who would not have surgery despite endometrial cancer were excluded from the study.

Locations (1)

Merve Demir

Kocaeli, Turkey (Türkiye)

Outcomes

Primary Outcomes

serum sL1CAM level

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.